Poor targeting of therapeutics leading to severe adverse effects on normal tissues is
considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug …

One of the challenges in cancer chemotherapy is the low target to non-target ratio of
therapeutic agents which incur severe adverse effect on the healthy tissues. In this regard …

A targeted delivery system based on the polymeric nanoparticles as a drug carrier
represents a marvelous avenue for cancer therapy. The pivotal characteristics of this system …

The epidermal growth factor receptor (EGFR) belongs to the tyrosine kinase receptors family
and is present in the epithelial cell membrane. Its endogenous activation occurs through the …

Chemotherapy, a major strategy for cancer treatment, lacks the specificity to localize the
cancer therapeutics in the tumor site, thereby affecting normal healthy tissues and …

Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has
achieved considerable success and progress over the past decades. Nevertheless …

The focus of nanoparticle design over the years has evolved toward more complex
nanoscopic core–shell architecture using a single delivery system to combine multiple …

Gemcitabine, an anticancer agent which acts against a wide range of solid tumors, is known
to be rapidly deaminated in blood to the inactive metabolite 2′, 2′-difluorodeoxyuridine …

Combination chemotherapy is a common practice in clinical management of malignancy.
Synergistic therapeutic outcome is only achieved when tumor cells are exposed to cells in …

The 'nanomedicine'approach has revolutionized cancer therapy by enabling the packaging
of therapeutic agents within engineered nanovehicles that can specifically accumulate …